文献-镇痛||A型毒素的镇痛缺点

典籍-镇痛||A型毒以次使用缠GABA节阻截病患比较简单全球性呼吸困难症候群

A型以次使用缠GABA节阻截病患比较简单全球性呼吸困难症候群：一项随机检验

Max背景：Max

本研究者用以验证以次通过持续升高皮肤高温延长缠GABA阻截持续时间的结论。作者进行时了一项随机、双盲、对照检验，研究者a型以次病患比较简单全球性呼吸困难症候群患儿缠GABA节阻截的病理。

Max法则：Max

选用75 IU A型以次（以次第三组）和发散药（对照第三组），对下肢比较简单全球性呼吸困难症候群患儿进行时缠GABA节阻截。

主要结果是1个同月后阻截侧足底与对侧足底的相对温差变化。

次要结果是3个同月后的相对温差变化以及呼吸困难强度变化。

Max结果：Max

计有48名参与者（N=24/第三组）被随机分配。

以次第三组的相对高温减小略低于对照第三组（分作1.0±1.3℃ vs. 0.1±0.8℃；差异：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维持至术后3个同月，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与对照第三组相对，以次第三组在1个同月（分作（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个同月（分作（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的呼吸困难强度显著降低。

没有与以次口服相关的严重不良事件。

Max论点：Max

在比较简单全球性呼吸困难症候群患儿中会，采用A型以次进行时缠GABA节阻截可使患足高温升高3个同月，并可减轻呼吸困难。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.